Stocklytics Platform
Asset logo for symbol ABBV
AbbVie
ABBV62
$180.00arrow_drop_up0.90%$1.62
S&P500
Asset logo for symbol ABBV
ABBV62

$180.00

arrow_drop_up0.90%
Key Stats
Open$178.41
Prev. Close$178.39
EPS2.86
Next Earnings DateMay 16, 2025
LOWHIGH
Day Range177.25
180.14
52 Week Range135.85
207.59
Ratios
EPS2.86
Fundamentals
Industry average yield2.90%
Last Dividend pay dateFeb 14, 2025

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

—Strong Buy
—Buy
—Neutral
—Sell
—Strong Sell

Analyst rating

An aggregate view of professional's ratings.

—Strong Buy
—Buy
—Neutral
—Sell
—Strong Sell

Stock Performance

ABBV-
US Healthcare Sector-
US Market-
warning

ABBV / Market

ABBV lose to the US Market which returned 1.00% over the last twenty four hours.
warning

ABBV / Healthcare Sector

ABBV lose to the US Healthcare sector which returned 2.95% over the last twenty four hours.

AbbVie (ABBV) Statistics

AbbVie Inc, ABBV is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative therapies. The company's stock statistics show a positive trend, with consistent growth in the stock price over the years. With a market capitalization of over $100 billion, AbbVie Inc is one of the largest players in the pharmaceutical industry. Its valuation metrics indicate a healthy financial position and market value. The stock fundamentals reflect strong revenue and earnings growth, making AbbVie Inc an attractive investment option.
When comparing AbbVie Inc's stock performance to the sector, it is evident that the company has outperformed its peers. The stock has consistently generated higher returns for investors, showcasing the company's ability to thrive in a competitive market. The revenue per share for AbbVie Inc is impressive, indicating a strong sales performance and efficient operation. Additionally, the Enterprise to EBITDA ratio, which measures the company's ability to generate earnings from its operations, is favorable for AbbVie Inc.
add AbbVie to watchlist

Keep an eye on AbbVie

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has AbbVie (ABBV) stock's performance compared to its sector and the market over the past year?

Over the past year, AbbVie (ABBV) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 25.34%, AbbVie has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 47.67%, it has fallen short of the market average. This comparison highlights AbbVie 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of AbbVie (ABBV) stock?

The PE (Price to Earnings) ratio of AbbVie (ABBV) is currently 62.94. This metric is used to evaluate the valuation of a company's stock, comparing its current share price relative to its per-share earnings.
help

What is the EPS of AbbVie (ABBV) stock?

The Earnings Per Share (EPS) for AbbVie (ABBV), calculated on a diluted basis, is $2.86. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of AbbVie (ABBV) stock?

The operating margin for AbbVie (ABBV) is 28.93%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of AbbVie (ABBV) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of AbbVie (ABBV) is $19.46B. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does AbbVie (ABBV) have?

AbbVie (ABBV) has a total debt of $71.32B. The net debt, which accounts for cash and cash equivalents against the total debt, is $63.82B.

Take Your Investments to a Whole New Level